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Background
Helicobacter pylori Infections
H. pylori is a gram-negative, spiral-shaped bacteria1. This bacteria has different adaptations that
allow it to remain in the gastrointestinal tract, such as flagella to assist with resisting contractions
produced by the small intestine1. H. pylori also produces an enzyme called urease, which alkalinizes the
harsh, acidic environment in the stomach, making it a more habitable place to live1,2. H. pylori infections
can cause serious problems for patients, starting with chronic gastritis or ulcers in the stomach, small
intestine, or esophagus1-6. A seemingly benign infection can eventually progress to gastric lymphoma or
cancer, and H. pylori is technically considered a carcinogen1-4,6-8. Infection is correlated with low
socioeconomic status2-4,6,9, low education level3,9, and African American race3,4. H. pylori infection has a
genetic component4 and is transmitted amongst families living in the same household1,9. Therefore,
someone whose parent or sibling has had a gastric ulcer or stomach cancer caused by H. pylori is more
likely to have H. pylori colonization1.

Diagnostic Testing for H. pylori
There are three main objective methods used to diagnose a patient with an H. pylori infection.
The first method, a urease breath test, is by far the most convenient method. This test measures urease
activity produced by the bacteria. While noninvasive, inexpensive and convenient, follow-up results
after treatment may have the potential to be falsely negative. If a patient has taken antibiotics and a
proton-pump inhibitor <4 weeks before administration of the test, it may not be able to detect the small
amount of resistant bacteria still present in the stomach1.
Biopsy-based testing is usually done in the hospital setting. Biopsies involve an endoscopy
procedure that obtains a sample from the stomach. This type of testing is considered the “gold
standard” of diagnostic H. pylori testing1. Obtaining a sample of actual bacteria also allows the ability to
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determine sensitivities to antibiotics. While biopsy-based testing is very specific, it only evaluates a small
portion of the stomach and may not be completely sensitive to H. pylori presence. It is also invasive and
expensive1.
The other method of testing mentioned in the ACG guidelines is fecal antigen testing. Fecal
antigen testing involves looking for the presence of antigens to H. pylori in the stool. This option is costeffective for many patients but is not used as widely as the urea breath test. Fecal antigen testing results
can also be affected by antibiotic and proton-pump inhibitor (PPI) use so waiting at least four weeks
after discontinuing antibiotics is crucial for an accurate result10.

Treatment Options
There are multiple treatment options for treating H. pylori infections, and most treatment
options include two or more antibiotic classes in conjunction with a PPI2,4-5,8. The main workhorses of
treating an H. pylori infection are the macrolide and fluoroquinolone (FQ) classes of antibiotics.
Macrolides include erythromycin, clarithromycin, and azithromycin. Commonly used fluoroquinolones
include levofloxacin and ciprofloxacin. The most recent American College of
Gastroenterology (ACG) H. pylori treatment guidelines provide specific recommendations for using
these antibiotics based on kidney function, previous antibiotic exposure, and whether or not the
infection is a reoccurrence4. The most common regimens seen at St. Vincent’s primary care
centers mimic the ACG guidelines and include the bismuth quadruple (bismuth subsalicylate, a PPI,
tetracycline, and metronidazole) and clarithromycin triple (PPI, clarithromycin, and amoxicillin OR
metronidazole) regimens. The ACG’s recommended first-line treatment for an initial H. pylori infection is
specified in Table 1.
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Table 1. Guideline-directed initial H. pylori treatment therapy4
Presence

Previous macrolide exposure

of true
penicillin
allergy

Yes

No

Yes

No

Bismuth quadruple

Bismuth quadruple

Levofloxacin triple

Clarithromycin triple*

Levofloxacin sequential

Concomitant

Bismuth quadruple

Clarithromycin tripleꝉ
Bismuth quadruple

Bismuth quadruple: PPI + Bismuth subcitrate/subsalicylate + Tetracycline + Metronidazole x 10-14 days
Clarithromycin triple: PPI + Clarithromycin + Amoxicillin OR Metronidazole x 14 days
*with Amoxicillin
ꝉwith Metronidazole
Levofloxacin triple: PPI + Levofloxacin + Amoxicillin x 10-14 days
Levofloxacin sequential: PPI + Amoxicillin x 5-7 days, then add Levofloxacin + Nitroimidazole x an add’l 5-7 days
Concomitant: PPI + Clarithromycin + Amoxicillin + Nitroimidazole x 3-10 days4

Need for Study
Antibiotic Resistance Overview
Unfortunately, macrolides and fluoroquinolones are among the worst culprits for inducing
antibiotic resistance, which has impacted the ability to successfully treat H. pylori. In fact, in 2017 the
World Health Organization (WHO) named H. pylori a high priority bacterium for antibiotic research and
development due to high rates of resistance2,11-12. Antibiotic resistance can arise when mutations occur
in the genetic material of bacteria that change the way the bacteria respond to the antibiotic. In
macrolides’ case, a mutation occurs at the ribosome (site that the drugs bind to) and decreases the
macrolides’ affinity for the ribosome2,4-5,11,13-14. For fluoroquinolones, the bacteria develop DNA changes
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in the enzyme that these drugs bind to (DNA gyrase) and limits binding ability of fluoroquinolones2,4,11,14.
Eventually H. pylori’s ability to synthesize and replicate its DNA are diminished14. This can lead to
infections that aren’t cured by first-choice regimens and the need to use less optimal, more expensive
antibiotics with undesirable side effects arises. It has been shown that susceptibility of the bacteria to
the antibiotic regimen is the greatest determinant of treatment success4-6,8. Metronidazole is also a
medication commonly used for H. pylori that has significant worldwide resistance, but this project will
not focus on these rates as this resistance can often be overcome by increasing the treatment dose or
duration4,8,14. Amoxicillin and tetracycline (TCN) are also used commonly in H. pylori treatment
regimens, but their resistance rates are consistently very low worldwide2,4,6,8,11,14 and will not be focused
on in this project.

Helicobacter pylori Resistance
Resistance can occur by many mechanisms, such as the overuse and overprescribing of
antibiotics. In general, it has been proven that countries who have high resistance rates have higher
prescription antibiotic consumption8,14. When looking at the H. pylori organism specifically, it has
previously been proven that H. pylori eradication rates are higher in patients who have previously
received a macrolide5. As shown in Table 1, the most recent ACG guidelines recommend that if a patient
has been exposed to a medication in the macrolide class of antibiotics that they should avoid using
another macrolide, since there is a high probability that the H. pylori in their stomach will have
developed resistance to it during the previous exposure4-6,11. There have been multiple studies that
explore H. pylori’s increasing resistance rates around the world. The commonly accepted resistance rate
threshold for a medication that indicates the highly resistant medication class should be avoided and
another agent should be chosen is >15%4,6,8. Past this threshold, H. pylori treatment success rates
significantly decline.
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Worldwide resistance rates sorted by region were collected in a 2018 meta-analysis and can be
found in Table 26. As shown in Table 2, many parts of the world have resistance rates greater than the
accepted threshold for treating with clarithromycin or levofloxacin6. H. pylori contracted in a different
part of the world may be more resistant to initial antibiotic treatment strategies used in the United
States. Thus, it may be beneficial to take recent travel and home country into account when selecting an
initial H. pylori treatment regimen. One region that was recognized for significant levels of H. pylori
resistance is Latin America. While one meta-analysis shows the American region to have a resistance
rate at or below the 15% threshold6 and another shows overall resistance rate in Latin America to be
only 12%8, there is variety between actual countries. In 2007, the countries with the highest
consumption of macrolides per capita were Venezuela, Argentina, and Chile8. The same three countries
saw a significant increase in fluoroquinolone use over a ten-year period8. Peru had the highest
prevalence of H. pylori resistance at 50%8. In contrast, Mexico, Uruguay, and Colombia saw decreases in
their macrolide use8 and the lowest clarithromycin resistance rate was well below the threshold at 2% in
Paraguay8. Given this wide variety of resistance rates among Latin America, each country’s resistance
rates should be taken into consideration to determine whether clarithromycin or levofloxacin is
appropriate for initial treatment. Along with differing resistance rates, there is a large part of the
population that has increased activity of the enzyme that metabolizes the PPI component of treatment,
CYP2C198. This may decrease the effectiveness of the PPI, as it is being cleared too fast to have a
therapeutic effect.
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Table 2. Primary Resistance Rates of Clarithromycin and Levofloxacin by World Region6
Region

Clarithromycin Resistance

Levofloxacin Resistance Rate

Rate
Africa Region

15%

14%

10%

15%

33%

19%

18%

11%

10%

30%

34%

19%

Cameroon, Congo, Senegal

Americas Region
Argentina, Brazil, Canada,
Colombia, Peru, USA

Eastern Mediterranean
Region
Egypt, Iran, Morocco, Pakistan,
Saudi Arabia

European Region
Austria, Belgium, Bulgaria, Croatia,
France, Germany, Greece,
Iceland, Ireland, Israel, Italy,
Poland, Spain, Netherlands,
Turkey, UK,
Multicentric/International

Southeast Asia Region
Bangladesh, Bhutan, India,
Indonesia, Thailand

Western Pacific Region
Australia, China, Japan, South
Korea, Laos, Malaysia, New
Zealand, Singapore, Taiwan,
Vietanam
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While there is a good idea of resistance rates of other countries, there is not a good estimate of
the resistance rates specific to the United States, let alone the Indianapolis patient population. The most
recent study done by the Houston VA Medical Center reported resistance rates for clarithromycin to be
16% and levofloxacin to be 31%16.

Objectives
Since resistance to H. pylori is such a significant problem worldwide and resistance rates are
not well published in America, more definitive data is needed to determine whether St. Vincent’s
prescribed regimens are truly resulting in successful eradication of H. pylori infections, and whether
protocol to incorporate the risk of resistance as a treatment regimen determinant need to be
formulated. The main objective of this project is to identify what percentage of H. pylori infections
diagnosed at St. Vincent’s Family Medicine and Internal Medicine clinics are being successfully treated
with current, guideline-directed therapy. The secondary objective of this project is to obtain a general
understanding of H. pylori resistance rates to clarithromycin and levofloxacin in the Indianapolis area
based on treatment failure rates. Any conclusions able to be drawn about local resistance and how
Indianapolis compares to the rest of the world may help guide future treatment decisions among
prescribers.

Methods
This project was a retrospective chart review that looks at past patient data from St. Vincent’s
Internal Medicine and Family Medicine clinics. St. Vincent’s electronic medical record, Athena, was used
for chart review. St. Vincent’s pharmacy services database, Enterprise, was used to obtain prescription
filling information. All data was extracted to and managed using the Ascension installation of REDCap
(Research Electronic Data Capture). REDCap provides a secure way to track data while ensuring proper
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handling of personal identifying information (PHI)17,19. This project did not require an Institutional
Review Board approval; instead, the project was approved by St. Vincent’s Quality Improvement
Committee.

Inclusion Criteria
Patients in the review were > 18 years old at the time of diagnosis, patients at either St.
Vincent’s Internal Medicine or Family Medicine clinics and were diagnosed with H. pylori in between the
date range of February 1st, 2017 to August 31st, 2018. The beginning of this date range falls
approximately one month after the most recent ACG guidelines were published. A patient list was
generated using a query from Athena using the ICD codes B96.81 (H. pylori as the cause of diseases
classified elsewhere), K29.70 (gastritis, unspecified, without bleeding) or A04.8 (bacterial infections
intestinal).

Data Collection
Each patient’s labs, clinical documents, medications, fill history and relevant outside records
were reviewed and pertinent patient information was documented in REDCap. This information was
used to fill in a pre-written questionnaire; items on the questionnaire can be found in Table 3. These
questions were written in yes-no format whenever possible; other choices were multiple choice and
written response. For multiple choice answers, an “Other” category was given for treatment decisions
that did not match pre-populated answers.
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Table 3. Relevant Patient Data Components
H. pylori diagnosis (Y/N)
Presence of allergy to any component of the treatment regimen
Prescription for a macrolide or a fluoroquinolone in the last year
Presence of drug interactions with patient’s existing medication list at start of regimen
Type of H. pylori treatment regimen (clarithromycin triple, bismuth quadruple, etc.)
Zip code patient lives in Indianapolis or within 25 miles of Indianapolis
Recent travel outside the United States within 1 year and country of destination
Diagnostic test used to diagnose H. pylori infection (Urea breath test, fecal antigen test, or
biopsy-based test)
Diagnosis date of H. pylori
Methods of follow-up and timing in relation to completion of treatment regimen
Presence of clinic visits starting 4 weeks after treatment completion with H. pylori symptoms or
another positive diagnosis of H. pylori
Whether or not the prescriptions were filled
Whether or not the prescriptions were picked up by the patient
Patient picked up medications prescribed for H. pylori (all, some, or none)
What type of second line treatment regimen was prescribed, if applicable, and whether or not it was
appropriate.
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Whether or not the patient was diagnosed with H. pylori and diagnosis date of H. pylori were
collected to exclude those who did not fit the criteria of the project. Presence of allergies to any
component of the treatment regimen were collected to identify improper treatment initiation. It was
also used to identify potential reasoning for failed treatment, since an allergic reaction could have
potentially resulted in stopping the treatment regimen prematurely and/or result in a delay of infection
resolution. Prior fluoroquinolone use is not mentioned in the ACG guidelines but was collected
regardless to explore the possibility that prior use may impact successful therapy, since
fluoroquinolones are another class of antibiotics that are notorious for high resistance rates. Zip code
was collected to ensure the patient lives in Indianapolis or within a 25-mile radius. This ensures that the
data collected will accurately reflect the typical Indianapolis patient population. Recent travel outside
the United States within 1 year and to where was collected to determine whether the patient may be
harboring H. pylori from other countries where resistance rates to clarithromycin or levofloxacin may be
higher or lower than the appropriate threshold of >15%. Fill rates were determined by using Enterprise
for patients who filled at St. Vincent’s Pharmacy and by looking at insurance claims for patients filling at
an outside pharmacy. This was collected to assess whether the patient was truly taking the regimen that
was prescribed. Choice of treatment regimen, prior macrolide use within one year, diagnostic testing
methods, methods and timing of follow-up, and second-line treatment for failed treatment were
collected to ensure recommendations made by the ACG guidelines were followed appropriately. Each
patient’s home medication regimen charted on that day and the H. pylori treatment regimen prescribed
was assessed using Lexicomp’s drug interaction report to assess any potential that therapy could be
rendered less effective.
Each individual patient was assessed by the researcher using the objective data above and the
ACG guidelines as guidance and was sorted into “Failed,” “Successful,” or “Unknown Outcome” groups.
Each patient was also determined to have received “Appropriate” or “Inappropriate” therapy. The
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“Inappropriate” group was further explored to try and determine potential protocol changes that may
assist healthcare team members in improving H. pylori treatment. The “Failed” treatment group was
assessed in tandem with their appropriateness of therapy to try and determine whether causes of
failure stemmed from potential resistance to treatment or inappropriate therapy.

Results
Patient Characteristics
There were 105 patient records that were populated through the EMR inquiry. Forty-one
patients either received tests for H. pylori that resulted in a negative result or were diagnosed with a
different gastric condition, such as gastritis. These patients were excluded from analysis. The remaining
sixty-four patient records were analyzed.
The mean age of the total population was 44.31 years old, with a standard deviation of 14.75
years. The youngest patient in the group was 18.99 years and the oldest patient was 81.27 years. All
patients initially identified through Athena lived in an address with a zip code that was within a 25-mile
radius of Indianapolis (105 out of 105).
Out of the 64 patients that were diagnosed with H. pylori, the urea breath test (UBT) was the
most commonly used diagnostic test with 42 patients. There were 4 patients that were diagnosed using
fecal antigen testing and 15 patients that were diagnosed using a biopsy-based test. Two patients were
not tested and 1 patient’s record did not specify what test was given.
There were 6 patients that had allergies to one or more medications in the treatment regimens.
Five out of six patients had penicillin allergies documented; none received amoxicillin-containing
regimens. One patient had a documented allergy to omeprazole; the first-line regimen contained
pantoprazole instead and no adverse effects from the pantoprazole were documented.
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An overwhelming 46 out of 64 patients required translator services, with the majority (32 out of
46) speaking Spanish. There were a total of 10 different languages spoken amongst those needing
translators. A complete breakdown of native languages can be found, along with additional analysis of
patient population parameters, in Figure 1.

Figure 1.
Patient age
Total
Count Missing Unique Min
(N)
105

0
(0.0%)

105

Percentile
Max Mean StDev

Sum

0.05

0.10

0.25

18.99 81.27 44.31 14.75 4,653.07 22.44 25.73 33.65

0.50
0.75
Median
43.41

0.90

54.14 65.59 71.40

Lowest values: 18.990123000472288, 19.414612666014133, 19.885532671216154, 21.829332566719373,
22.094909546397258
Highest values: 72.64214870941909, 74.97484547937329, 75.00507653590878, 76.32737154082561,

81.27476950245385

Figure 1., continued.
Initial Diagnostic Testing

Native Languages
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0.95

Treatment
For brevity, regimens will be abbreviated; please see Table 5 for an abbreviation guide. Of the
first-line treatments prescribed for the 64 patients diagnosed with H. pylori, the CTA regimen was the
highest prescribed regimen with 27 patients. This regimen is made up of clarithromycin 500 mg,
amoxicillin 1 gram, and a PPI of normal or double strength dosage4. All medications are taken twice daily
for 14 days.
The second highest treatment for initial therapy was the “Other” category consisting of 19
patients. This category was made up of all regimens that did not follow the recommendations made in
the guidelines. The most common regimen in the “Other” category was an MBQ regimen, with 11
patients. The standard BQ regimen is normally made up of a PPI taken twice a day plus bismuth
subcitrate or subsalicylate, metronidazole 250-500 mg, and tetracycline 500 mg taken four times a day
for 10-14 days. In the MBQ regimen the tetracycline is replaced by doxycycline, a derivative of
tetracycline that has a similar mechanism of action. There were two patients that received PPIs alone;
the reason documented in the chart for both patients was pregnancy. A complete breakdown of initial
treatment options can be found in Figure 2.
Three patients had received a macrolide within 1 year of H. pylori treatment initiation. One
patient was still prescribed the CTA regimen, one patient received the BQ regimen (non-macrolide
containing), and one patient received hybrid therapy with clindamycin replacing the clarithromycin
component. Three patients had received a fluoroquinolone prescription within 1 year of H. pylori
treatment initiation, and all three were appropriately treated with non-fluoroquinolone containing
regimens.
There were 44 identified drug interactions; some patients had one interaction and a select few
had two interactions. There were 2 interactions where no action was needed (category B), 8 interactions
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where increased monitoring was necessary (category C), and 22 interactions where modification should
have been considered (category D). The most frequent category D interaction was an interaction
between the tetracycline/doxycycline and bismuth subsalicylate of the BQ and MBQ regimens. Nineteen
patients received the BQ or MBQ regimens; the interaction populated for each of these patients. There
were only two interactions in which there was a chance of decreased concentration of an antibiotic.
Clarithromycin-diazepam was one of these interactions; in this case the patient was only taking as
needed for seizures. The other interaction was doxycycline and sucralfate, which could have been
clinically significant. The rest of the interactions were related to increased toxicity of home medications.

Figure 2.
First Line Treatments
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Table 5.
Abbreviation Guide
BQ

Bismuth quadruple

MBQ

Modified Bismuth quadruple

CTA

Clarithromycin triple w/amoxicillin

CTM

Clarithromycin triple w/metronidazole

LS

Levofloxacin sequential

LT

Levofloxacin triple

Follow-Up and Second-Line Therapy
Thirty-five patients out of 64 received follow-up testing after completion of therapy. The urea
breath test remained the most popular testing method in follow-up therapy with 28 patients, followed
by 6 patients with fecal antigen testing and 1 patient with a biopsy-based test.
Out of the 35 patients who were retested, 11 patients had positive H. pylori test results.
Curiously, 15 patients were given second-line treatment, which indicates four patients were given
second-line therapy without being re-tested. Bismuth quadruple was the most common choice for
second-line therapy with 7 patients. Of the 15 patients prescribed second-line therapy, 11 patients’
regimens were deemed appropriate. Complete analysis of second-line therapy can be found in Figure 3.
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Figure 3.
Follow-Up Testing

Second-Line Therapies

Appropriateness and Success of Therapy
Overall treatment regimen, treatment duration, follow-up testing procedures, and relevant drug
interactions were observed on Athena to determine the appropriateness of therapy. Patients who filled
at St. Vincent’s pharmacy were determined adherent or nonadherent by looking at fill history through
Enterprise. For patients who filled at an outside pharmacy, presence of insurance claims were relied on
to determine adherence to the regimen. Absence of an insurance claim from an outside pharmacy was
deemed not picked up and was considered inappropriate therapy. Any progress notes by providers were
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also read to look for notes about adherence. Only 15 patients received appropriate therapy out of the
64 patients who received H. pylori treatment. The biggest determinant of inappropriate therapy for the
remaining patients was the absence of follow-up testing (30.9% of errors), followed up by adherence
issues (25% of errors) and an incorrect regimen being prescribed (16.7% of errors). A complete analysis
can be found in Figure 4.
Without taking appropriateness of therapy into account, there were 18 successful treatments
defined by an appropriate negative follow-up H. pylori test and 15 failed treatments defined by a
positive follow-up H. pylori test. There were 24 patients whose outcomes could not be determined due
to lack of follow-up, and there were 7 patients who had negative H. pylori tests taken <4 weeks of
antibiotic therapy, leaving the possibility of a falsely negative test. This information can also be found in
Figure 4.

Figure 4
Inappropriate Therapy

Overall Treatment Outcomes
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Discussion
H. pylori infection continues to be a significant issue among patients in the United States. It can
be a difficult infection to treat, as it has been shown that different countries have varying levels of
resistance6,8,15. A meta-analysis that looked at treatment eradication rates of the bismuth quadruple and
clarithromycin triple therapy and found that while the overall eradication rates were 77.6% and 68.9%
respectively, a high heterogeneity between the trials was found20. In this project, the overall H. pylori
eradication rate of patients with a known outcome was slightly lower at 54.5%. Of the 8 patients who
received the BM regimen first-line, 4 had negative H. pylori tests, making the eradication rate lower at
around 50%. The CTA regimen had an even lower eradication rate of around 37%. When adjusted to
only include patients with known outcomes, the eradication rates become 80% and 55.6%, respectively.
While our data was limited by sample size and the amount of patients lost to follow-up and with
unknown outcomes, this project still provides comparable eradication rates to current data.
The variety of different treatment options can make it challenging for providers to choose an
appropriate regimen. The ACG guidelines have a total of eight first-line regimens to choose from, with
additional regimens developed for salvage therapy. In this project, it was discovered that an incorrect
regimen was the third highest reason for inappropriate treatment. Some of the incorrect regimens
contained pieces of the therapy recommended by the ACG but were missing key components. One of
the biggest misunderstood regimens in this project was the bismuth quadruple regimen, as many
prescribers substituted doxycycline in place of tetracycline.
While replacing tetracycline with doxycycline may seem reasonable given their identical
mechanisms of action and similarities in structure21,22, there are some significant differences in
doxycycline that may lower effectiveness of the regimen. Tetracycline and doxycycline have differences
in protein binding; tetracycline has protein binding of about 55%-65%21 while doxycycline is highly
protein bound at >90%22. This may result in lower concentrations of the drug being systemically
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absorbed because it is binding to protein in the plasma at a higher degree. Protein-bound drug does not
have systemic action since it remains in the plasma. While not extensively demonstrated in this project,
highly protein bound drugs can interact with other highly protein bound drugs and increase the risk of
toxicity. The bioavailability of doxycycline also becomes reduced at higher stomach pH22. Tetracycline
does not have this reported effect21. This may be important because these patients will be taking
concomitant PPIs, which reduce acid production in the stomach and therefore make the stomach
environment more alkalotic. Concomitant use of these two medications together may result in less
doxycycline being absorbed and available for treatment of the infection.
The data on substituting doxycycline for tetracycline is conflicting; a 1992 study found that only
65% of patients taking a modified bismuth triple therapy (regimen did not include the PPI component)
achieved eradication of H. pylori compared to 92% of patients taking a traditional regimen containing
tetracycline (p = 0.004)23,24. There are more recent studies that replace the metronidazole component
with amoxicillin in addition to replacing tetracycline with doxycycline taken twice a day that have had
some successful results24-26. However, there is no way to extrapolate this data to use doxycycline with a
traditional bismuth quadruple regimen containing metronidazole. No head-to-head studies comparing
bismuth quadruple therapy to a modified bismuth quadruple therapy with doxycycline exist at this time.
Given the lack of data and the discouraging results using doxycycline with metronidazole in a bismuth
triple regimen, it may be best practice to avoid replacing tetracycline with doxycycline until additional
data is published.
The heterogeneity of eradication rates20 and the variety in resistance rates around the world6,8
make it difficult to choose an appropriate regimen. Finding recent places of travel in Athena proved to
be a challenge and place of origin is not consistently documented in Athena, so this project’s
representation of possible H. pylori infections from other countries is limited and wholly unreliable.
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However, while countries of origin and travel were difficult to find, need for a translator was
found to be consistently documented among all patients. As shown in Figure 1., this project’s small
patient population was extremely diverse, encompassing ten different languages from all over the
world. At St. Vincent, in-house translators are available for Spanish-speaking patients but for other
languages, a telephone or video interpreter is used. Historically, patients who receive interpreter
services in a practice setting overall receive significantly more recommended preventative services,
made more office visits, and had more prescriptions written and filled27. However, while telephone
translation is more cost-effective and convenient, problems such as inadequate clarity of sound, inability
of the interpreter to respond to visual cues from the provider and patient, and cultural barriers in which
some patients are uncomfortable speaking with an unknown voice28 can impact the effectiveness of
using the service.
Language is not the only difference among patients from other countries. There are many
different cultural factors that may hinder a patient’s adherence. Among minority populations, an
inherent distrust of the health system may exist due to perceived inequal treatment of minority
populations29.
Low socioeconomic class is also another barrier to adherence. Many of the patients in our
project were self-pay and did not have insurance coverage. Pricing of individual medications can vary
significantly based on pharmacy, but for someone without insurance tetracycline itself is over $300 for a
14-day supply30, and a full bismuth quadruple regimen may cost even more. Other patients were
Medicaid or Medicare patients, which may result in forcing treatment options that are covered instead
of the ones truly indicated on an individual patient basis.
Patient understanding is key in multi-drug regimens such as those used in H. pylori treatment,
and the language barrier and culture can make this treatment even more difficult. In Arab patients,
there is a belief that obtaining healthcare is important, but ultimately true recovery comes from God31.
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They may not view the H. pylori regimen as important for eradication as providers or those of other
cultures, so it is important to respectfully acknowledge this belief and stress the importance of taking
the complete regimen. In addition, some cultures, particularly Hispanic patients, may view illness as evil
done by another person or outside source29. This may limit the perceived importance of preventative
medicine such as follow-up treatment and annual exams. Certain cultures may rely on other herbal or
alternative medicine therapies29,31, which may interact with components of the antibiotic regimen. For
instance, both garlic and honey can be used for symptoms of gastritis, but both can interact with
Cytochrome P 450 (CYP) 3A4 enzyme substrates32,33, such as clarithromycin. This can increase risk of
toxicity or lower effectiveness if taken together.
Of all identified adherence issues, 80% occurred with patients who needed a translator. Of
patients who needed a translator, 76.1% had inappropriate therapy of some kind. Of patients lost to
follow-up, a vast majority (~88%) required a translator. Translation services are a great start in trying to
expand healthcare services to non-English speaking patients, but our project showed that it isn’t doing
quite enough. Options to increase cultural awareness may include involving social work professionals,
respectfully inquiring the patient about their individual beliefs about health care and treatment, and
avoiding stereotypes based on age or race29. Staff education about various cultures and their beliefs
would also be beneficial in better understanding patients’ views of the healthcare system. Overall, a
more inclusive approach to other cultures healthcare preferences would benefit both the provider and
the patient.

Weaknesses
This project was a retrospective chart review of a small sample size, so it is limited in its capacity
to expand to other institutions. Because H. pylori has such diverse infection and resistance rates around
the world, however, it is difficult to establish consistency among multiple locations. The time frame
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started only one month after the ACG guidelines were released, so there is the possibility that old
guidance was still being used for treatment decisions.
A significant weakness during this study was looking only at whether patients had visited a
different country within one year of diagnosis. H. pylori can often be asymptomatic for years before
causing issues for patients4, and a one-year time frame may have been inappropriate in determining
where their H. pylori infections originated. As mentioned previously, Athena did not have consistent
reporting of travel habits and patients were not often questioned about them during these visits. In
addition, there were situations in which a patient may not have been traveling but had family members
who had multiple risk factors for H. pylori infection. According to the ACG guidelines, if one family
member has H. pylori, other family members are at higher risk for contracting H. pylori as well1,3-4,9.
Looking at birth country, race, and socioeconomic status may have been more insightful to determine
possible contraction location and to explore additional risk factors.

Conclusion
While this project was not truly able to assess whether ACG-guideline directed therapy is
resulting in successful eradication to a large degree, it was able to identify inconsistencies between St.
Vincent’s treatment habits and the ACG guidelines. Poor follow-up testing is a significant barrier to
completely eradicating H. pylori and preventing the long-term risks that come with infection.
This project was also able to identify that an underserved population makes up the majority of
H. pylori infection cases. These patients are already at risk of successful treatment and H. pylori
regimens of multiple drugs several times a day may compound that risk. This project was able to break
down the main reasons that patients are treated inappropriately and identify potential areas of protocol
change that can help increase patient’s chances of completely eradicating H. pylori infections.
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